FDA Approval of Kerendia to Assist Gradual Kidney Illness and Failure Related to Kind 2 Diabetes

WASHINGTON, July 15, 2021 / PRNewswire / – The American Association of Kidney Patients, the largest consumer and care organization for kidney patients in the United States, today developed the following statement regarding the recent FDA approval of the new drug therapy Kerendia by Bayer Pharmaceuticals, to slow the progression of chronic kidney disease and reduce the risk of kidney failure in adult patients with chronic kidney disease associated with type 2 diabetes. Since its inception in 1969, AAKP has been the leading independent, patient-centric voice for greater investment and innovation in kidney disease research, detection and treatment. The AAKP is known nationwide for its aggressive advocacy for consumers of kidney patients and its right to choose treatment in consultation with the doctors treating them. AAKP defines quality kidney care as patients’ timely access to prevention and treatment innovations that enable them to stay healthy, independent, and able to pursue their goals, including meaningful work and career, home ownership, starting and supporting a family, and a safe retirement.

“The American Association of Kidney Patients, as the largest kidney patient organization in the country, welcomes the recent FDA approval of Kerendia in light of the significant medical advancement and hopes this will represent kidney patient consumers and their decade-long demand for more innovation to support Slowing the Effects of Chronic Kidney Disease Associated with Type 2 Diabetes, Including Loss of Kidney Function and Kidney Failure Kidney disease has an incredibly alarming, growing and disproportionate impact on minority communities, and the burden and cost is borne by the patient, their families, and the world American Taxpayers. We look forward to informing elected leaders, government agencies and payers that timely access to this treatment when it is considered medically beneficial between doctors and their patients d sure has priority. Unnecessary interference with these medical decisions or delays in patient access are contrary to the principle of patient care and the long-standing national goal of promoting innovation and new tools to slow kidney disease, reduce kidney failure, and reduce the number of Americans who may be on dialysis or the kidney transplant waiting list. ”

AAKP works closely with government officials, medical researchers, industry leaders and investors working to restore kidney patient consumers to their rightful place at the center of all kidney health, innovation, research and policy decisions. The organization provides original data from surveys of renal patients and expert advice to government, industry, think tank, and academia executives involved in engaging and recruiting patients for research studies, technical review panels, advisory boards, clinical trials, and substantial patient engagement efforts. Data across the entire product development lifecycle – including regulatory and payment decisions.

In 2019, AAKP launched The Decade of the Kidney™, an international patient consortium aiming to mobilize patient consumers and their allies to encourage executives and decision makers to invest more in kidney research and more sensible strategies to accelerate innovation in kidney drugs, diagnostics and devices, including artificial kidneys. Since 2019, AAKP, in partnership with The George Washington University School of Medicine and Health Sciences, hosted the Global Summit on Kidney Disease Innovations (See the sessions on OnDemand in 2021), which has grown into the largest patient-led and virtual global kidney gathering, attended by over 80 countries and 20,000 spectators in 2021™ Program, the first voter registration initiative for kidney patients, their families, and the broader community of kidney stakeholders, including healthcare professionals. Based on the success of KidneyVoters in 2020™, AAKP has announced it will enroll half a million patients and kidney advocates by 2024.

About the American Association of Kidney Patients (AAKP): Founded in 1969, the AAKP is the largest kidney patient organization driving policy discussions about patient care choices and treatment innovations for kidney patients. By 1973, the AAKP patient collaborations with the US Congress and the White House helped ensure dialysis insurance for all those with kidney failure, creating the only disease-specific, taxpayer-funded entitlement program in America. This CMS-managed program, the End Stage Renal Disease Program (ESRD), has saved over a million lives. Over the past decade, AAKP patients have helped achieve lifelong drug transplantation for kidney transplant recipients (2020); new patient-centered guidelines on the White House Executive Order to Promote American Kidney Health (2019); new occupational protection for organ living under the Family Medical Leave Act (FMLA) of the US Department of Labor (2018); and Congressional Legislation Allowing HIV-Positive Organ Transplants for HIV-Positive Patients (2013). The AAKP’s virtual platforms and social networks are internationally known for their effectiveness. Follow AAKP on social media at @kidneypatient on Facebook and @kidneypatients on Twitter and visit our website at https://aakp.org/.

MEDIA CONTACT:
Jennifer rate
Marketing and Communication Manager
(813) 400-2394
[email protected]

SOURCE The American Association of Kidney Patients

similar links

https://aakp.org